"目录号: HY-13679
Others-
2-mercaptoethane sulfonate (Mesna)是化疗保护剂，可用于环磷酰胺诱导的出血性膀胱炎。
Others
相关产品
SBE-β-CD-MPTP hydrochloride-Cyclosporin A-Etomoxir-Auranofin-GKT137831-Ceruletide-Acetylcysteine-JC-1-BPTES-Brassinolide-FCCP-IPTG-MTT-RSL3 1S,3R--
生物活性
Description
2-mercaptoethane sulfonate (Mesna), is a synthetic small molecule, widely used as a systemic protective agent against chemotherapy toxicity, but is primarily used to reduce hemorrhagic cystitis induced by cyclophosphamide.IC50 Value: 182 mM (decreased superoxide anion production stimulated with PMA (tetradecanoylphorbol acetate) in PMN in-vitro); 70mM (inhibited H2O2 production) [3]Target: in vitro: MESNA had no effect on the qualitative and quantitative characteristics of the indicated processes in both the types of the doxorubicin sensitive cells. The combined use of doxorubicin and phosphamide or cyclophosphane the use of MESNA for lowering the urotoxic action of oxazophosphorines had no effect on the biological efficacy of doxorubicin [4].in vivo: AMH-positive follicles were significantly decreased after cisplatin administration, which was significantly reversed when mesna was co-administered with cisplatin. The end product of lipid peroxidation, malondialdehyde (MDA), was significantly increased, but the anti-oxidative enzymatic activity of superoxide dismutase (SOD) and glutathione (GSH) were significantly decreased in cisplatin groups when compared with NS group. In contrast, after co-administration of cisplatin with mesna, MDA was significantly decreased whereas the activity of SOD and the concentration of GSH were increased. Moreover, mesna did not decrease the anti-tumor property of cisplatin in HePG2 cell lines [2]. After head trauma, tissue malondialdehyde levels increased; these levels were significantly decreased by MESNA administration. Caspase-3 levels were increased after trauma, but no effect of MESNA was determined in caspase-3 activity [1].Clinical trial: Effects of Mesna on Homocysteine in Kidney Failure . Phase2
Clinical Trial
NCT00524199
Lawson Health Research Institute-Canadian Institutes of Health Research (CIHR)
End Stage Renal Disease
March 2007
Phase 2
NCT01205503
Mara Chambers-University of Kentucky
Breast Cancer-Non-Hodgkin's Lymphoma
September 2010
Phase 2
NCT00758667
Vanderbilt University
Implant Capsular Contracture
January 2005
NCT00001300
National Cancer Institute (NCI)-National Institutes of Health Clinical Center (CC)
Sarcoma
June 1992
Phase 3
NCT00006260
Case Comprehensive Cancer Center-National Cancer Institute (NCI)
Breast Cancer
May 1997
Phase 2
NCT00286403
Southeast Renal Research Institute-Dialysis Clinic, Inc.
Acute Renal Failure
August 2008
Phase 2-Phase 3
NCT00006373
H. Lee Moffitt Cancer Center and Research Institute-National Cancer Institute (NCI)
Lymphoma
February 2000
Phase 2
NCT00588094
Memorial Sloan Kettering Cancer Center
Lymphoma-B-cell Non-Hodgkin's Lymphoma
October 2003
Phase 2
NCT00450801
University of Miami
Lymphoma
April 2004
Phase 2
NCT00878254
University of Miami
Mantle-Cell Lymphoma
March 25, 2009
Phase 2
NCT00093509
Mark Dewhirst-National Cancer Institute (NCI)-Duke University
Sarcoma
November 1999
Phase 1-Phase 2
NCT01749072
Peking Union Medical College Hospital
Non-small Cell Lung Cancer-Effects of Chemotherapy
December 2012
Phase 2
NCT01331590
Washington University School of Medicine
Precursor Cell Lymphoblastic Leukemia-Lymphoma
July 2011
Early Phase 1
NCT01501149
Mingzhi Zhang-Second Hospital of Shanxi Medical University-Shanxi Province Cancer Hospital-Wuhan University-Wuhan TongJi Hospital-Wuhan Union Hospital, China-Qingdao University-Cancer Hospital of Guizhou Province-Xinyang Central Hospital-The First Affiliated Hospital of Henan University of Traditional Chinese Medicine-Zhengzhou University
Nasal and Nasal-type NK/T-cell Lymphoma
January 2011
Phase 4
NCT00578344
Baylor College of Medicine-Texas Children's Hospital-The Methodist Hospital System
Sickle Cell Disease-Hemoglobin SC
July 2005
NCT01481272
Polish Lymphoma Research Group
Diffuse Large B Cell Lymphoma
November 2011
Phase 2
NCT00439361
M.D. Anderson Cancer Center-Millennium Pharmaceuticals, Inc.
Hodgkin Lymphoma-Lymphoma
February 2007
Phase 1
NCT01590732
M.D. Anderson Cancer Center-Celgene Corporation
Lymphoma
October 2012
Phase 1
NCT00292695
National Health Research Institutes, Taiwan-Mackay Memorial Hospital-National Cheng-Kung University Hospital-Taichung Veterans General Hospital-Taipei Veterans General Hospital, Taiwan-Kaohsiung Veterans General Hospital.-National Taiwan University Hospital-Tri-Service General Hospital-Chi Mei Medical Hospital-Kaohsiung Medical University-Changhua Christian Hospital-Buddhist Tzu Chi General Hospital
Lymphoma
May 2006
Phase 2
NCT00578461
Baylor College of Medicine-Texas Children's Hospital
Leukemia-Cancer-Lymphoma-Lymphoma, Hodgkin-Lymphoma, Non-Hodgkin
October 2007
NCT03172052
Assiut University
Pleural Effusion
August 1, 2017
Phase 4
NCT03056339
M.D. Anderson Cancer Center-Bellicum Pharmaceuticals
B-Lymphoid Malignancies-Acute Lymphocytic Leukemia-Chronic Lymphocytic Leukemia-Non-hodgkin Lymphoma
June 21, 2017
Phase 1-Phase 2
NCT01955460
M.D. Anderson Cancer Center-Cancer Prevention Research Institute of Texas
Melanoma
October 2014
Phase 1
NCT00504751
Weill Medical College of Cornell University-Millennium Pharmaceuticals, Inc.
Non-Hodgkin's Lymphoma
May 2007
Phase 2
NCT00958256
M.D. Anderson Cancer Center-Millennium Pharmaceuticals, Inc.
Mantle Cell Lymphoma-Lymphoma
August 2009
Phase 2
NCT00177047
Masonic Cancer Center, University of Minnesota
Multiple Myeloma
April 20, 2004
Phase 2-Phase 3
NCT01329900
M.D. Anderson Cancer Center-Novartis
Lymphoma
August 2011
Phase 2
NCT00698009
M.D. Anderson Cancer Center
Neuroblastoma
June 2008
Phase 2
NCT01169636
M.D. Anderson Cancer Center-Novartis
Hodgkin's Lymphoma
January 31, 2011
Phase 1-Phase 2
NCT00941928
M.D. Anderson Cancer Center
Leukemia-Pediatric Cancer
July 2009
Phase 2
NCT00578539
Baylor College of Medicine-Center for Cell and Gene Therapy, Baylor College of Medicine-Texas Children's Hospital
Leukemia-Hodgkin Lymphoma-Non Hodgkin Lymphoma-Myeloproliferative Disorders
October 2007
NCT01740557
M.D. Anderson Cancer Center-National Institutes of Health (NIH)-National Cancer Institute (NCI)-Prometheus Laboratories-Key Biologics, LLC
Melanoma
January 28, 2015
Phase 1-Phase 2
NCT02732015
M.D. Anderson Cancer Center-Tesaro, Inc.
Sarcoma
October 2016
Phase 2
NCT02106988
M.D. Anderson Cancer Center
Lymphoma
January 2015
Phase 2
NCT02167958
University of Pittsburgh
Leukemia-MDS-Myelofibrosis-Lymphoma
November 2014
Phase 1
NCT02500576
M.D. Anderson Cancer Center-Merck Sharp & Dohme Corp.-Prometheus Inc.
Melanoma
August 7, 2015
Phase 2
NCT02212574
Sidney Kimmel Comprehensive Cancer Center
Medulloblastoma
March 2015
NCT00578292
Baylor College of Medicine-Texas Children's Hospital
Thalassemia
February 2004
NCT00857389
M.D. Anderson Cancer Center
Stem Cell Transplantation-Leukemia-Lymphoma
March 2009
Phase 2
NCT02877303
M.D. Anderson Cancer Center-Amgen
Leukemia-Acute Lymphoblastic Leukemia
November 2016
Phase 2
NCT01371630
M.D. Anderson Cancer Center-Pfizer
Leukemia-Acute Lymphoblastic Leukemia
August 2011
Phase 1-Phase 2
NCT01904136
M.D. Anderson Cancer Center-Cancer Prevention Research Institute of Texas
Leukemia-Myeloproliferative Diseases
April 2014
Phase 1-Phase 2
NCT00038610
M.D. Anderson Cancer Center-Novartis Pharmaceuticals
Leukemia
March 2001
Phase 2
NCT00002941
Children's Oncology Group-National Cancer Institute (NCI)
Lymphoma
April 1998
Phase 2
NCT00924287
National Cancer Institute (NCI)-National Institutes of Health Clinical Center (CC)
Metastatic Cancer
November 2008
Phase 1-Phase 2
NCT01670084
Mayo Clinic
B-cell Adult Acute Lymphoblastic Leukemia-Blastic Phase Chronic Myelogenous Leukemia-Chronic Myelogenous Leukemia, BCR-ABL1 Positive-Philadelphia Chromosome Positive Adu